3.250USD-2.99%Mkt Cap: 192.81M $P/E: 1.721d ago
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringe…
Industry Peers
Medical Instruments & Supplies$122.33BUSDP/E 39.6
$83.33BUSDP/E 33.5
$70.90BUSDP/E 34.9
$43.58BUSDP/E 27.6
$31.56BUSDP/E 42.0
$28.86BUSDP/E 19.2
$25.31BUSDP/E 48.0
$19.64BUSDP/E 67.5
$18.05BUSDP/E 44.5
$18.27BUSDP/E 103.6
$14.52BUSDP/E 81.9
$13.88BUSDP/E 45.2
$14.08BUSDP/E 10.0
$13.99BUSDP/E 60.8
$12.66BUSDP/E 29.7
$11.68BUSD
$8.46BUSDP/E 22.7
$8.31BUSDP/E 161.8
$7.56BUSD
$5.67BUSDP/E 23.2
$5.96BUSDP/E 2692.2
$4.61BUSDP/E 31.0
$4.75BUSD
$4.41BUSDP/E 31.9
$4.35BUSDP/E 65.2
$4.00BUSDP/E 40.2
$3.94BUSDP/E 84.7
$3.63BUSDP/E 16.3
$3.36BUSDP/E 21.6
$3.24BUSDP/E 2641.0
$2.79BUSDP/E 21.4
$2.60BUSD
$2.81BUSD
$2.32BUSDP/E 37.4
$1.88BUSDP/E 33.0
$1.98BUSD
$1.77BUSD
$1.43BUSD
$1.42BUSD
$1.25BUSDP/E 62.5
$1.32BUSD
$1.21BUSD
$1.09BUSD
$822.54MUSD
$745.86MUSDP/E 15.9
$761.22MUSDP/E 14.9
$675.68MUSDP/E 39.4
$659.76MUSDP/E 55.8
$558.40MUSD
$354.63MUSDP/E 20.8
$350.60MUSDP/E 16.9
$266.44MUSD
$244.96MUSDP/E 13.5
$229.10MUSDP/E 416.7
$207.13MUSDP/E 34.9
$222.24MUSDP/E 20.7
$198.25MUSDP/E 23.8
$188.78MUSD
$183.20MUSDP/E 15.8
$151.41MUSD
$154.12MUSD
$121.82MUSDP/E 38.7
$115.11MUSD
$117.54MUSD
$106.20MUSD
$63.64MUSDP/E 6.6
$59.94MUSD
$47.50MUSD
$41.04MUSDP/E 54.0
$41.23MUSDP/E 41.0
$38.65MUSD
$32.66MUSD
$28.10MUSD
$25.49MUSDP/E 177.7
$20.49MUSD
$15.94MUSD
$14.75MUSD
$14.55MUSD
$13.20MUSD
$8.63MUSDP/E 14.8
$9.09MUSD
$6.92MUSD
$5.07MUSD
$4.35MUSD
$465.9KUSD
$138.6KUSD
Indicators:|
| Headline | Source | Time |
|---|---|---|
This week | ||
 Embecta (EMBC) Stock Fair Value Moves Lower As Analysts Reset Medtech Expectations Embecta is in focus after one fair value estimate was reset from US$15.00 to US$4.00, which highlights how much some analysts have reworked their view of what the stock might be worth under updated assumptions. That shift sits alongside commentary pointing to a tougher setup for medtech valuations, higher inflation and capital flowing toward data center stocks, all of which are shaping how investors think about Embecta today. As you read on, you will see what is driving this evolving... | ||
Older | ||